A female in her early 30s with a previous history of postpartum granulomatous hypophysitis presented with palpitations and a syncopal episode. She was haemodynamically unstable on arrival with a heart ...
Solid Biosciences announces Phase 1b trial for SGT-501, a gene therapy for catecholaminergic polymorphic ventricular tachycardia, with FDA designations. Solid Biosciences Inc. has announced the ...
ARMGO Pharma, Inc. (ARMGO), a clinical stage biopharmaceutical company advancing a novel class of small molecule drugs known as Rycals®, announced today the enrollment of the first patient in a Phase ...
Researchers have developed a novel method for simultaneously recording action potentials (APs)—temporary changes in electrical potential when cells become excited—and calcium transients—calcium ...
CHARLESTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and ...
- Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatening, arrhythmogenic cardiac condition - - Solid ...
As reviewed earlier, termination of reentrant tachycardia requires critical timing of the pacing stimulus. Success or failure of the pacing stimulus to interact with and terminate tachycardia, is ...
While sports can be risky for kids with arrhythmogenic cardiac conditions, researchers are now reporting four cases in which video games triggered syncope from ventricular tachycardia or fibrillation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results